

Buparvaquone Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 03/23/2020
4.1	10/10/2020	2091185-00007	Date of first issue: 10/17/2017

SECTION 1. IDENTIFICATION

Product name : Buparvaquone Formulation
Other means of identification : No data available

Manufacturer or supplier's details

Company name of supplier : Merck & Co., Inc
Address : 2000 Galloping Hill Road
Kenilworth - New Jersey - U.S.A. 07033
Telephone : 908-740-4000
Telefax : 908-735-1496
Emergency telephone : 1-908-423-6000
E-mail address : EHSDATASTEWARD@merck.com

Recommended use of the chemical and restrictions on use

Recommended use : Veterinary product

SECTION 2. HAZARDS IDENTIFICATION**GHS classification in accordance with the Hazardous Products Regulations**

Skin irritation : Category 2
Eye irritation : Category 2A
Reproductive toxicity : Category 1B
Specific target organ toxicity : Category 3
- single exposure

GHS label elements

Hazard pictograms :



Signal Word : Danger

Hazard Statements : H315 Causes skin irritation.
H319 Causes serious eye irritation.
H335 May cause respiratory irritation.
H360D May damage the unborn child.

Precautionary Statements : **Prevention:**
P201 Obtain special instructions before use.
P202 Do not handle until all safety precautions have been read and understood.
P261 Avoid breathing mist or vapors.
P264 Wash skin thoroughly after handling.
P271 Use only outdoors or in a well-ventilated area.
P280 Wear protective gloves, protective clothing, eye protection and face protection.

Buparvaquone Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 03/23/2020
4.1	10/10/2020	2091185-00007	Date of first issue: 10/17/2017

Response:

P302 + P352 IF ON SKIN: Wash with plenty of water.

P304 + P340 + P312 IF INHALED: Remove person to fresh air and keep comfortable for breathing. Call a doctor if you feel unwell.

P305 + P351 + P338 IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing.

P308 + P313 IF exposed or concerned: Get medical attention.

P332 + P313 If skin irritation occurs: Get medical attention.

P337 + P313 If eye irritation persists: Get medical attention.

P362 + P364 Take off contaminated clothing and wash it before reuse.

Storage:

P405 Store locked up.

Disposal:

P501 Dispose of contents and container to an approved waste disposal plant.

Other hazards

None known.

SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture : Mixture

Components

Chemical name	CAS-No.	Concentration (% w/w)
N-Methyl-2-pyrrolidone	872-50-4	$\geq 30 - < 60$ *
Coconut Oil	8001-31-8	$\geq 30 - < 60$ *
Buparvaquone	88426-33-9	$\geq 5 - < 10$ *

* Actual concentration or concentration range is withheld as a trade secret

SECTION 4. FIRST AID MEASURES

General advice : In the case of accident or if you feel unwell, seek medical advice immediately.
When symptoms persist or in all cases of doubt seek medical advice.

If inhaled : If inhaled, remove to fresh air.
Get medical attention.

In case of skin contact : In case of contact, immediately flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Get medical attention.
Wash clothing before reuse.

In case of eye contact : Thoroughly clean shoes before reuse.
In case of contact, immediately flush eyes with plenty of water for at least 15 minutes.
If easy to do, remove contact lens, if worn.

Buparvaquone Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 03/23/2020
4.1	10/10/2020	2091185-00007	Date of first issue: 10/17/2017

If swallowed	: Get medical attention. If swallowed, DO NOT induce vomiting. Get medical attention. Rinse mouth thoroughly with water.
Most important symptoms and effects, both acute and delayed	: Causes skin irritation. Causes serious eye irritation. May cause respiratory irritation. May damage the unborn child.
Protection of first-aiders	: First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).
Notes to physician	: Treat symptomatically and supportively.

SECTION 5. FIRE-FIGHTING MEASURES

Suitable extinguishing media	: Water spray Alcohol-resistant foam Carbon dioxide (CO ₂) Dry chemical
Unsuitable extinguishing media	: None known.
Specific hazards during fire fighting	: Exposure to combustion products may be a hazard to health.
Hazardous combustion products	: Carbon oxides Nitrogen oxides (NO _x)
Specific extinguishing methods	: Use extinguishing measures that are appropriate to local circumstances and the surrounding environment. Use water spray to cool unopened containers. Remove undamaged containers from fire area if it is safe to do so. Evacuate area.
Special protective equipment for fire-fighters	: In the event of fire, wear self-contained breathing apparatus. Use personal protective equipment.

SECTION 6. ACCIDENTAL RELEASE MEASURES

Personal precautions, protective equipment and emergency procedures	: Use personal protective equipment. Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).
Environmental precautions	: Avoid release to the environment. Prevent further leakage or spillage if safe to do so. Prevent spreading over a wide area (e.g., by containment or oil barriers). Retain and dispose of contaminated wash water. Local authorities should be advised if significant spillages cannot be contained.
Methods and materials for containment and cleaning up	: Soak up with inert absorbent material. For large spills, provide diking or other appropriate containment to keep material from spreading. If diked material can be pumped, store recovered material in appropriate container. Clean up remaining materials from spill with suitable

Buparvaquone Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 03/23/2020
4.1	10/10/2020	2091185-00007	Date of first issue: 10/17/2017

absorbent.

Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable.

Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

SECTION 7. HANDLING AND STORAGE

- | | | |
|-----------------------------|---|---|
| Technical measures | : | See Engineering measures under EXPOSURE CONTROLS/PERSONAL PROTECTION section. |
| Local/Total ventilation | : | If sufficient ventilation is unavailable, use with local exhaust ventilation. |
| Advice on safe handling | : | Do not get on skin or clothing.
Avoid breathing mist or vapors.
Do not swallow.
Do not get in eyes.
Wash skin thoroughly after handling.
Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment
Keep container tightly closed.
Already sensitized individuals should consult their physician regarding working with respiratory irritants or sensitizers.
Take care to prevent spills, waste and minimize release to the environment. |
| Conditions for safe storage | : | Keep in properly labeled containers.
Store locked up.
Keep tightly closed.
Keep in a cool, well-ventilated place.
Store in accordance with the particular national regulations. |
| Materials to avoid | : | Do not store with the following product types:
Strong oxidizing agents
Organic peroxides
Explosives
Gases |

SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Ingredients with workplace control parameters

Components	CAS-No.	Value type (Form of exposure)	Control parameters / Permissible concentration	Basis
N-Methyl-2-pyrrolidone	872-50-4	TWA	400 mg/m ³	CA ON OEL
Coconut Oil	8001-31-8	TWAEV (Mist)	10 mg/m ³	CA QC OEL
Buparvaquone	88426-33-9	TWA	20 µg/m ³ (OEB 3)	Internal
Further information: Skin				
		Wipe limit	200 µg/100 cm ²	Internal

Buparvaquone Formulation

Version 4.1 Revision Date: 10/10/2020 SDS Number: 2091185-00007 Date of last issue: 03/23/2020
 Date of first issue: 10/17/2017

Biological occupational exposure limits

Components	CAS-No.	Control parameters	Biological specimen	Sampling time	Permissible concentration	Basis
N-Methyl-2-pyrrolidone	872-50-4	5-Hydroxy-N-methyl-2-pyrrolidone	Urine	End of shift (As soon as possible after exposure ceases)	100 mg/l	ACGIH BEI

Engineering measures : Use appropriate engineering controls and manufacturing technologies to control airborne concentrations (e.g., drip-less quick connections).
 All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.
 Containment technologies suitable for controlling compounds are required to control at source and to prevent migration of the compound to uncontrolled areas (e.g., open-face containment devices).
 Minimize open handling.

Personal protective equipment

Respiratory protection : If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.

Filter type : Combined particulates and organic vapor type

Hand protection

Material : Chemical-resistant gloves

Remarks : Consider double gloving.

Eye protection : Wear safety glasses with side shields or goggles.
 If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles.
 Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.

Skin and body protection : Work uniform or laboratory coat.
 Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable suits) to avoid exposed skin surfaces.
 Use appropriate degowning techniques to remove potentially contaminated clothing.

Hygiene measures : If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place.
 When using do not eat, drink or smoke.
 Wash contaminated clothing before re-use.
 The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the

Buparvaquone Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 03/23/2020
4.1	10/10/2020	2091185-00007	Date of first issue: 10/17/2017

use of administrative controls.

SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES

Appearance	:	liquid
Color	:	clear, red
Odor	:	No data available
Odor Threshold	:	No data available
pH	:	No data available
Melting point/freezing point	:	No data available
Initial boiling point and boiling range	:	No data available
Flash point	:	No data available
Evaporation rate	:	No data available
Flammability (solid, gas)	:	Not applicable
Flammability (liquids)	:	No data available
Upper explosion limit / Upper flammability limit	:	No data available
Lower explosion limit / Lower flammability limit	:	No data available
Vapor pressure	:	No data available
Relative vapor density	:	No data available
Relative density	:	1 (20 °C)
Density	:	No data available
Solubility(ies)		
Water solubility	:	No data available
Partition coefficient: n-octanol/water	:	Not applicable
Autoignition temperature	:	No data available
Decomposition temperature	:	No data available
Viscosity		
Viscosity, kinematic	:	No data available
Explosive properties	:	Not explosive

Buparvaquone Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 03/23/2020
4.1	10/10/2020	2091185-00007	Date of first issue: 10/17/2017

Oxidizing properties : The substance or mixture is not classified as oxidizing.

Particle size : Not applicable

SECTION 10. STABILITY AND REACTIVITY

Reactivity : Not classified as a reactivity hazard.

Chemical stability : Stable under normal conditions.

Possibility of hazardous reactions : Can react with strong oxidizing agents.

Conditions to avoid : None known.

Incompatible materials : Oxidizing agents

Hazardous decomposition products : No hazardous decomposition products are known.

SECTION 11. TOXICOLOGICAL INFORMATION**Information on likely routes of exposure**

Inhalation
Skin contact
Ingestion
Eye contact

Acute toxicity

Not classified based on available information.

Product:

Acute oral toxicity : Acute toxicity estimate: > 5,000 mg/kg
Method: Calculation method

Components:**N-Methyl-2-pyrrolidone:**

Acute oral toxicity : LD50 (Rat): 4,150 mg/kg

Acute inhalation toxicity : LC50 (Rat): > 5.1 mg/l
Exposure time: 4 h
Test atmosphere: dust/mist
Method: OECD Test Guideline 403

Acute dermal toxicity : LD50 (Rat): > 5,000 mg/kg

Coconut Oil:

Acute oral toxicity : LD50 (Rat): > 5,000 mg/kg

Acute dermal toxicity : LD50 (Guinea pig): > 3,000 mg/kg
Assessment: The substance or mixture has no acute dermal toxicity
Remarks: Based on data from similar materials

Buparvaquone:

Buparvaquone Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 03/23/2020
4.1	10/10/2020	2091185-00007	Date of first issue: 10/17/2017

Acute oral toxicity : LD50 (Rat): > 8,000 mg/kg
LD50 (Mouse): > 50 mg/kg
Remarks: No mortality observed at this dose.

Acute toxicity (other routes of administration) : LD50: 2.5 mg/kg
Application Route: Intravenous

Skin corrosion/irritation

Causes skin irritation.

Components:**N-Methyl-2-pyrrolidone:**

Result : Skin irritation

Coconut Oil:

Species : Rabbit
Result : No skin irritation

Buparvaquone:

Species : Mouse
Result : Mild skin irritation

Serious eye damage/eye irritation

Causes serious eye irritation.

Components:**N-Methyl-2-pyrrolidone:**

Species : Rabbit
Result : Irritation to eyes, reversing within 21 days

Coconut Oil:

Species : Rabbit
Result : No eye irritation

Buparvaquone:

Result : Mild eye irritation

Respiratory or skin sensitization**Skin sensitization**

Not classified based on available information.

Respiratory sensitization

Not classified based on available information.

Buparvaquone Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 03/23/2020
4.1	10/10/2020	2091185-00007	Date of first issue: 10/17/2017

Components:**N-Methyl-2-pyrrolidone:**

Test Type	: Local lymph node assay (LLNA)
Routes of exposure	: Skin contact
Species	: Mouse
Method	: OECD Test Guideline 429
Result	: negative
Remarks	: Based on data from similar materials

Coconut Oil:

Test Type	: Maximization Test
Routes of exposure	: Skin contact
Species	: Guinea pig
Result	: negative

Germ cell mutagenicity

Not classified based on available information.

Components:**N-Methyl-2-pyrrolidone:**

Genotoxicity in vitro	: Test Type: Bacterial reverse mutation assay (AMES) Method: OECD Test Guideline 471 Result: negative
-----------------------	---

	Test Type: In vitro mammalian cell gene mutation test Method: OECD Test Guideline 476 Result: negative
--	--

	Test Type: DNA damage and repair, unscheduled DNA synthesis in mammalian cells (in vitro) Result: negative
--	---

Genotoxicity in vivo	: Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay) Species: Mouse Application Route: Ingestion Method: OECD Test Guideline 474 Result: negative
----------------------	---

	Test Type: Mutagenicity (in vivo mammalian bone-marrow cytogenetic test, chromosomal analysis) Species: Hamster Application Route: Ingestion Method: OECD Test Guideline 475 Result: negative
--	---

Coconut Oil:

Genotoxicity in vitro	: Test Type: Bacterial reverse mutation assay (AMES) Result: negative
-----------------------	--

Buparvaquone Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 03/23/2020
4.1	10/10/2020	2091185-00007	Date of first issue: 10/17/2017

Carcinogenicity

Not classified based on available information.

Components:**N-Methyl-2-pyrrolidone:**

Species	:	Rat
Application Route	:	Ingestion
Exposure time	:	2 Years
Result	:	negative

Species	:	Rat
Application Route	:	inhalation (vapor)
Exposure time	:	2 Years
Result	:	negative

Reproductive toxicity

May damage the unborn child.

Components:**N-Methyl-2-pyrrolidone:**

Effects on fertility	:	Test Type: Two-generation reproduction toxicity study Species: Rat Application Route: Ingestion Method: OECD Test Guideline 416 Result: negative
----------------------	---	--

Effects on fetal development	:	Test Type: Embryo-fetal development Species: Rat Application Route: Ingestion Method: OECD Test Guideline 414 Result: positive
------------------------------	---	--

	:	Test Type: Fertility/early embryonic development Species: Rat Application Route: inhalation (vapor) Result: positive
--	---	---

	:	Test Type: Embryo-fetal development Species: Rabbit Application Route: Ingestion Result: positive
--	---	--

Reproductive toxicity - Assessment	:	Clear evidence of adverse effects on development, based on animal experiments.
------------------------------------	---	--

STOT-single exposure

May cause respiratory irritation.

Components:**N-Methyl-2-pyrrolidone:**

Assessment	:	May cause respiratory irritation.
------------	---	-----------------------------------

Buparvaquone Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 03/23/2020
4.1	10/10/2020	2091185-00007	Date of first issue: 10/17/2017

STOT-repeated exposure

Not classified based on available information.

Repeated dose toxicity**Components:****N-Methyl-2-pyrrolidone:**

Species	: Rat, male
NOAEL	: 169 mg/kg
LOAEL	: 433 mg/kg
Application Route	: Ingestion
Exposure time	: 90 Days
Method	: OECD Test Guideline 408

Species	: Rat
NOAEL	: 0.5 mg/l
LOAEL	: 1 mg/l
Application Route	: inhalation (dust/mist/fume)
Exposure time	: 96 Days
Method	: OECD Test Guideline 413

Species	: Rabbit
NOAEL	: 826 mg/kg
LOAEL	: 1,653 mg/kg
Application Route	: Skin contact
Exposure time	: 20 Days

Buparvaquone:

Species	: Cat
NOAEL	: 10 mg/kg
Application Route	: Intramuscular
Exposure time	: 5 d
Remarks	: No significant adverse effects were reported

NOAEL	: 5 mg/kg
Application Route	: Intravenous
Exposure time	: 4 d
Remarks	: No significant adverse effects were reported

Species	: Mouse
NOAEL	: 50 mg/kg
Application Route	: Oral
Exposure time	: 6 d
Remarks	: No significant adverse effects were reported

Aspiration toxicity

Not classified based on available information.

Experience with human exposure**Components:****N-Methyl-2-pyrrolidone:**

Skin contact	: Symptoms: Skin irritation
--------------	-----------------------------

Buparvaquone Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 03/23/2020
4.1	10/10/2020	2091185-00007	Date of first issue: 10/17/2017

SECTION 12. ECOLOGICAL INFORMATION**Ecotoxicity****Components:****N-Methyl-2-pyrrolidone:**

- | | | |
|--|---|--|
| Toxicity to fish | : | LC50 (Oncorhynchus mykiss (rainbow trout)): > 500 mg/l
Exposure time: 96 h |
| Toxicity to daphnia and other aquatic invertebrates | : | EC50 (Daphnia magna (Water flea)): > 1,000 mg/l
Exposure time: 24 h
Method: DIN 38412 |
| Toxicity to algae/aquatic plants | : | ErC50 (Desmodesmus subspicatus (green algae)): 600.5 mg/l
Exposure time: 72 h

EC10 (Desmodesmus subspicatus (green algae)): 92.6 mg/l
Exposure time: 72 h |
| Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity) | : | NOEC (Daphnia magna (Water flea)): 12.5 mg/l
Exposure time: 21 d
Method: OECD Test Guideline 211 |
| Toxicity to microorganisms | : | EC50: > 600 mg/l
Exposure time: 30 min
Method: ISO 8192 |

Buparvaquone:

- | | | |
|---|---|--|
| Toxicity to fish | : | LC50 (Brachydanio rerio (zebrafish)): 0.484 mg/l
Exposure time: 96 h
Method: OECD Test Guideline 203 |
| Toxicity to daphnia and other aquatic invertebrates | : | EC50 (Daphnia magna (Water flea)): 0.013 mg/l
Exposure time: 48 h
Method: OECD Test Guideline 202 |

Persistence and degradability**Components:****N-Methyl-2-pyrrolidone:**

- | | | |
|------------------|---|---|
| Biodegradability | : | Result: Readily biodegradable.
Biodegradation: 73 %
Exposure time: 28 d
Method: OECD Test Guideline 301C |
|------------------|---|---|

Bioaccumulative potential**Components:****N-Methyl-2-pyrrolidone:**

- | | | |
|---------------------------|---|----------------|
| Partition coefficient: n- | : | log Pow: -0.46 |
|---------------------------|---|----------------|

Buparvaquone Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 03/23/2020
4.1	10/10/2020	2091185-00007	Date of first issue: 10/17/2017

octanol/water

Method: OECD Test Guideline 107

Buparvaquone:

Partition coefficient: n-octanol/water : log Pow: 6.5

Mobility in soil

No data available

Other adverse effects

No data available

SECTION 13. DISPOSAL CONSIDERATIONS**Disposal methods**

Waste from residues	: Dispose of in accordance with local regulations.
Contaminated packaging	: Empty containers should be taken to an approved waste handling site for recycling or disposal.
	If not otherwise specified: Dispose of as unused product.

SECTION 14. TRANSPORT INFORMATION**International Regulations****UNRTDG**

UN number	: UN 3082
Proper shipping name	: ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID, N.O.S. (Buparvaquone)
Class	: 9
Packing group	: III
Labels	: 9

IATA-DGR

UN/ID No.	: UN 3082
Proper shipping name	: Environmentally hazardous substance, liquid, n.o.s. (Buparvaquone)
Class	: 9
Packing group	: III
Labels	: Miscellaneous
Packing instruction (cargo aircraft)	: 964
Packing instruction (passenger aircraft)	: 964
Environmentally hazardous	: yes

IMDG-Code

UN number	: UN 3082
Proper shipping name	: ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID, N.O.S. (Buparvaquone)
Class	: 9
Packing group	: III
Labels	: 9
EmS Code	: F-A, S-F

Buparvaquone Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 03/23/2020
4.1	10/10/2020	2091185-00007	Date of first issue: 10/17/2017

Marine pollutant : yes

Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code

Not applicable for product as supplied.

Domestic regulation**TDG**

UN number	: UN 3082
Proper shipping name	: ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID, N.O.S. (Buparvaquone)
Class	: 9
Packing group	: III
Labels	: 9
ERG Code	: 171
Marine pollutant	: yes(Buparvaquone)

Special precautions for user

The transport classification(s) provided herein are for informational purposes only, and solely based upon the properties of the unpackaged material as it is described within this Safety Data Sheet. Transportation classifications may vary by mode of transportation, package sizes, and variations in regional or country regulations.

SECTION 15. REGULATORY INFORMATION**The ingredients of this product are reported in the following inventories:**

AICS	: not determined
DSL	: not determined
IECSC	: not determined

SECTION 16. OTHER INFORMATION**Full text of other abbreviations**

ACGIH BEI	: ACGIH - Biological Exposure Indices (BEI)
CA ON OEL	: Ontario Table of Occupational Exposure Limits made under the Occupational Health and Safety Act.
CA QC OEL	: Québec. Regulation respecting occupational health and safety, Schedule 1, Part 1: Permissible exposure values for air-borne contaminants
CA ON OEL / TWA	: Time-Weighted Average Limit (TWA)
CA QC OEL / TWA EV	: Time-weighted average exposure value

AIIC - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA

Buparvaquone Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 03/23/2020
4.1	10/10/2020	2091185-00007	Date of first issue: 10/17/2017

- International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

Sources of key data used to compile the Material Safety Data Sheet : Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, <http://echa.europa.eu/>

Revision Date : 10/10/2020
Date format : mm/dd/yyyy

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

CA / Z8